Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04294069 · ClinicalTrials.gov registry record · Phase 4

Azithromycin Dose and PPROM Treatment: a Pilot Randomized Controlled Trial

A Phase 4 study of Preterm Premature Rupture of Membrane, sponsored by Thomas Jefferson University.

Completed
Registry status
Phase 4
Development phase
6
Enrollment target
1
Study location

NCT04294069 is a Phase 4 study of Preterm Premature Rupture of Membrane that has completed, run by Thomas Jefferson University. The registered enrollment target is 6 participants. The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04294069, a Phase 4 study of Preterm Premature Rupture of Membrane, has completed, sponsored by Thomas Jefferson University.

COMPLETED
Registry status
Phase 4
Development phase
6 participants
Enrollment target
1
Study location

Study Summary

This is a pilot randomized controlled trial to assess the pharmacokinetics and pharmacodynamics of azithromycin in pregnant singletons admitted with preterm premature rupture of membranes (PPROM) at 24 0/7- 33 0/7. Participants will be randomized 1:1 to either 1000mg azithromycin orally once or 500mg azithromycin orally daily for seven days in addition to standard care.

Interventions

  • DRUG Azithromycin 500 mg
  • DRUG Azithromycin Oral Product

Study Locations (1)

Pennsylvania

  • Thomas Jefferson University Hospital - Philadelphia

Trial Details

FieldValue
Enrollment Target 6 participants
Start Date 2020-09-14
Est. Completion 2021-04-01
Phase Phase 4

Sponsor

Thomas Jefferson University

292 total trials

What the Registry Record Tells You About NCT04294069

The ClinicalTrials.gov registry entry for NCT04294069 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Thomas Jefferson University, which has 292 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Preterm Premature Rupture of Membrane appearing as the primary indexed condition, and to 2 interventions - of which Azithromycin 500 mg is the first listed.

NCT04294069 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT04294069 about?

NCT04294069 is a clinical study titled "Azithromycin Dose and PPROM Treatment: a Pilot Randomized Controlled Trial". This is a pilot randomized controlled trial to assess the pharmacokinetics and pharmacodynamics of azithromycin in pregnant singletons admitted with preterm premature rupture of membranes (PPROM) at 24 0/7- 33 0/7. Participants will be randomized 1:1 to either 1000mg azithromycin orally once or 500m...

What is the current status of trial NCT04294069?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 6 participants. The study started on 2020-09-14. Estimated completion is 2021-04-01.

What conditions does trial NCT04294069 study?

This clinical trial studies the following conditions: Preterm Premature Rupture of Membrane.

What interventions are being tested in trial NCT04294069?

The interventions under investigation include: Azithromycin 500 mg (DRUG), Azithromycin Oral Product (DRUG).

Who is sponsoring clinical trial NCT04294069?

This trial is sponsored by Thomas Jefferson University, which has 292 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04294069 being conducted?

This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Preterm Premature Rupture of Membrane

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.